| pathology | Demonstrated benefit and harm | k | | | |
|---|
| cardiovascular prevention | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Adriaensen, 1976 | Suloctidil 200 mg / j (n=15) vs. Placebo (n=15) | patients suffering from intermittent claudication ( stade II) | double blind Parallel groups Sample size: 15/15 Primary endpoint: Périmètre de marche FU duration: 2 months | | Verhaeghe, 1981 | Suloctidil 200 mg / j (n=-9) vs. Placebo (n=-9) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: -9/-9 Primary endpoint: Périmètre de marche FU duration: 6 months | | Jones, 1982 | Suloctidil 300 mg / j (n=18) vs. Placebo (n=22) | patients suffering from intermittent claudication (stade II) | double blind Parallel groups Sample size: 18/22 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 6 months | | Holm, 1984 | Suloctidil 300 mg / j (n=20) vs. Placebo (n=20) | AOMI stade II | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 2.75 y |
|
| peripheral vascular diseases | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Adriaensen, 1976 | Suloctidil 200 mg / j (n=15) vs. Placebo (n=15) | patients suffering from intermittent claudication ( stade II) | double blind Parallel groups Sample size: 15/15 Primary endpoint: Périmètre de marche FU duration: 2 months | | Verhaeghe, 1981 | Suloctidil 200 mg / j (n=-9) vs. Placebo (n=-9) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: -9/-9 Primary endpoint: Périmètre de marche FU duration: 6 months | | Jones, 1982 | Suloctidil 300 mg / j (n=18) vs. Placebo (n=22) | patients suffering from intermittent claudication (stade II) | double blind Parallel groups Sample size: 18/22 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 6 months | | Holm, 1984 | Suloctidil 300 mg / j (n=20) vs. Placebo (n=20) | AOMI stade II | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 2.75 y |
|
| thrombosis prevention | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Suloctidil vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Turpie, 1985 | Suloctidil (n=68) vs. Placebo (n=68) | | double-blind Sample size: 68/68 Primary endpoint: FU duration: |
|
